<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34728">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654483</url>
  </required_header>
  <id_info>
    <org_study_id>34182</org_study_id>
    <nct_id>NCT02654483</nct_id>
  </id_info>
  <brief_title>Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients</brief_title>
  <official_title>A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jean Yuh Tang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Epidermolysis Bullosa Research Partnership</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Menlo Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Itch, or pruritus, is the most common complain reported by patients with epidermolysis
      bullosa (EB) of all subtypes, and there is no current effective treatment. Itch often
      triggers scratching that creates new wounds and increases EB disease severity. This study
      aims to target the physiological mechanisms of pruritus. Substance P is a major mediator of
      pruritus and binds to the receptor neurokinin-1 (NK1), which is expressed in the central
      nervous system and the skin. VPD-737 (serlopitant), a drug that inhibits the NK1 receptor,
      has been shown to reduce severe itch in a previous study of 257 adult patients with chronic
      pruritus. The investigators are now testing VPD-737 in 14 patients with EB in a Phase II
      randomized, placebo-controlled, double-blinded clinical trial. Our goals is to determine
      whether daily oral administration of VPD-737 (5 mg) is effective and safe in adolescents and
      adults with EB.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients will complete a VAS every day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Itchman Scale</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stanford EB Itch Survey</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Epidermolysis Bullosa</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>5 mg VPD-737</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg tablets of VPD-737 to be taken daily by mouth for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets to be taken daily by mouth for 56 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VPD-737</intervention_name>
    <description>VPD-737 inhibits the receptor neurokinin-1.</description>
    <arm_group_label>5 mg VPD-737</arm_group_label>
    <other_name>Serlopitant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching tablets to VPD-737 tablets without active drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of epidermolysis bullosa and pruritus

        Exclusion Criteria:

          -  Have chronic liver or renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Tang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yana Dutt-Singh</last_name>
    <phone>(650) 721-7166</phone>
    <email>yanad@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yana Dutt-Singkh</last_name>
      <email>yanad@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 23, 2016</lastchanged_date>
  <firstreceived_date>January 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jean Yuh Tang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Epidermolysis Bullosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neurokinin A</mesh_term>
    <mesh_term>Substance P</mesh_term>
    <mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
